Two Phase 3 trials show that NT-501 encapsulated cell therapy significantly reduces ellipsoid zone area loss in Macular Telangiectasia Type 2. While functional outcomes were inconsistent, the treatment demonstrated a robust neuroprotective effect against photoreceptor degeneration over 24 months.